Submitted:
01 October 2025
Posted:
02 October 2025
You are already at the latest version
Abstract
Background: Typhoid fever (TF) is a systemic infection caused by Salmonella enterica serovar Typhi, typically associated with regions where sanitation and access to clean water are inadequate. Although rare in non-endemic countries, TF remains a diagnostic consideration in travelers returning from endemic areas with febrile illness. Case report: We present the case of an 18-year-old female who developed TF following recent travel to Nigeria. The initial clinical presentation, including fever, dysuria, and abdominal pain, led to a misdiagnosis of acute pyelonephritis. Malaria, arboviral infections, acute viral hepatitis, and parasitic diseases were systematically ruled out through clinical evaluation, serological testing, and parasitological analysis. The clinical course was marked by fever, abdominal pain, somnolence, and hematological and hepatic abnormalities. Blood cultures confirmed the diagnosis, with the isolate verified and serotyped by the National Center of Infectious and Parasitic Diseases. Targeted antimicrobial treatment with ceftriaxone and levofloxacin resulted in full recovery, with no evidence of relapse or chronic carriage over a three-month follow-up period. Conclusions: This case highlights the critical importance of a structured differential diagnostic approach and microbiological confirmation in febrile patients with relevant travel history. In non-endemic settings, where TF may be underrecognized, early recognition, pathogen identification, and appropriate antimicrobial therapy remain essential to favorable outcomes and public health safety.
Keywords:
1. Background
2. Case Presentation
3. Discussion
4. Conclusion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Artificial Intelligence Disclosure
Acknowledgments
Conflicts of Interest
References
- Pavlova M, Velev G, Kamenov E, Alexandrova E. Salmonella Typhi: klassika ili predizvikatelstvo. NCIPD, Sofia, 2019.
- Mileva S, Gospodinova M, Todorov I. Salmonella enteritidis primary bacteremia in previously healthy patient from Taiwan: case report. Ther Adv Infect Dis 2016; 3(5): 128–132. [CrossRef]
- Yang YA, Chong A, Song J. Why is eradicating typhoid fever so challenging: implications for vaccine and therapeutic design. Vaccines (Basel) 2018; 6(3): E45. [CrossRef]
- Mahmoud A, Oluyemisi A, Uwishema O, et al. Recent advances in the diagnosis and management of typhoid fever in Africa: a review. Health Sci Rep 2023; 6(3): e1167. [CrossRef]
- Johnston V, Stockley JM, Dockrell D, et al. Fever in returned travellers presenting in the United Kingdom: recommendations for investigation and initial management. J Infect 2009; 59(1): 1–18. [CrossRef]
- Brophy J; Committee to Advise on Tropical Medicine; Travel (CATMAT). Summary of the statement on international travellers who intend to visit friends and relatives. Can Commun Dis Rep 2015; 41(5): 89–99. [CrossRef]
- World Health Organization. World malaria report 2023. Geneva: WHO, 2023. ISBN: 978-92-4-008618-0.
- Huits R, Hamer DH, Libman M. Post-travel evaluation of the ill traveler. CDC Yellow Book: Health Information for International Travel [Internet] 2024 [cited 2025 Jun 16]. Available from: https://www.cdc.gov/yellow-book/hcp/post-travel-evaluation/post-travel-evaluation-of-the-ill-traveler.html.
- Francois Watkins LK, Shih DC, Dorough L. Typhoid and paratyphoid fever. CDC Yellow Book: Health Information for International Travel [Internet]. Ed. 2026. Atlanta (GA): Centers for Disease Control and Prevention; 2025 Apr 23 [cited 2025 Jun 16]. Available from: https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/typhoid-and-paratyphoid-fever.html.
- Klemm EJ, Shakoor S, Page AJ, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. mBio 2018; 9(1): e00105-18. [CrossRef]
| Test1−20 | 14.11 | 26.11 | Reference range |
| Hb, g/l1 | 100.0 | 116.0 | 120–160 |
| RBCc, x1012/l2 | 3.94 | 4.25 | 3.8–5.2 |
| Leucocytes, x109/l3 | 3.68 | 5.74 | 4.0–10.0 |
| Neutrophils, %4 | 70.7 | 55.7 | 40–75 |
| Basophils, %5 | 0.4 | 0.8 | 0–1 |
| Monocytes, %6 | 3.6 | 4.4 | 2–8 |
| Eosinophils, %7 | 0.0 | 0.1 | 0–5 |
| Lymphocytes, %8 | 25.3 | 35.8 | 20–45 |
| Plt, x109/l9 | 58 | 163 | 150–400 |
| Urea, mmol/l10 | 13.3 | 8.2 | 2.5–8.3 |
| Creatinine, μmol/l11 | 99 | 89 | 44–97 |
| Total protein, g/l12 | 51.0 | 69.5 | 64–83 |
| Albumin, g/l13 | 25.0 | 34.0 | 35–52 |
| ALT, U/l14 | 680.0 | 108.0 | <40 |
| AST, U/l15 | 2586.0 | 85.0 | <40 |
| GGT, U/l16 | 140.0 | 41.0 | <38 |
| CRP, mg/l17 | 174.0 | 16.09 | <5 |
| Na, mmol/l18 | 129.0 | 135.0 | 135–145 |
| K, mmol/l19 | 3.3 | 3.7 | 3.5–5.1 |
| Cl, mmol/l20 | 95.0 | 101.0 | 98–107 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).